MedTrace Logo

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 825

Last updated 2025-06-10

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions

  • Cough
  • Refractory Chronic Cough

Interventions

DRUG

BLU-5937

Oral administration of BLU-5937 Tablets

DRUG

Placebo

Oral administration of matching placebo for BLU-5937 Tablets

Sponsors & Collaborators

  • Bellus Health Inc. - a GSK company

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-25
Primary Completion
2025-12-18
Completion
2026-05-28
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Belgium
  • Canada
  • Colombia
  • France
  • Hungary
  • India
  • Israel
  • Netherlands
  • Poland
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05599191 on ClinicalTrials.gov